title: Coronary stents, hypersensitivity reactions, and the Kounis syndrome.
abstract: The use of drug-eluting stents (DES) for the treatment of coronary stenosis has increased sharply and now accounts for more than 75% of all coronary stents utilized. However, concern has been increasing that DES could be associated with stent thrombosis, paradoxical coronary vasoconstriction, and hypersensitivity reactions. Components of currently used DES have been reported to induce, either separately or synergistically, hypersensitivity reactions and possibly lead to cardiac events. DES-activated intracoronary mast cells could release histamine, arachidonic acid metabolites, proteolytic enzymes, as well as a variety of cytokines, chemokines, and platelet-activating factor (PAF) leading to local inflammation and thrombosis. These events may be more common than suspected because it is hard to document them, unless they become systemic, in which case they manifest themselves as the "Kounis syndrome," characterized by the concurrence of acute coronary events with hypersensitivity reactions. Recognition of this problem may lead to better vigilance, as well as new DES with mast cell blocking molecules that may also be disease modifying.
authors: Department of Medical Sciences, School of Health Sciences, Patras Highest Institute of Education and Technology, Queen Olgas Square, Patras, Greece. ngkounis@otenet.gr
authors: Nicholas G
authors: NG
authors: Kounis
authors: George
authors: G
authors: Hahalis
authors: Theoharis C
authors: TC
authors: Theoharides
mesh_terms: D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D023903:Coronary Restenosis / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004342:Drug Hypersensitivity / Q000209:etiology*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D017239:Paclitaxel; D012307:Risk Factors; D014661:Vasoconstriction
chemical_list: D017239:Paclitaxel